Company

Sorriso Pharmaceuticals, Inc.

Sorriso Pharmaceuticals develops oral antibody therapies for immune-mediated diseases.

About

Founded in 2020 and based in San Diego, Sorriso Pharmaceuticals is developing oral antibody programs including SOR101, SOR102 and SOR104 for immune-mediated diseases such as ulcerative colitis. It raised USD 31 mn in Series A funding in December 2021, co-led by New Enterprise Associates and Arix Bioscience.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in